Top

Published in:

01-11-2005 | Review Article

Neoplastic fever: a neglected paraneoplastic syndrome

Authors: Jason A. Zell, Jae C. Chang

Published in: Supportive Care in Cancer | Issue 11/2005

Abstract

Neoplastic fever, a paraneoplastic syndrome caused by cancer itself, represents a diagnostic challenge for the clinician and is an important issue in supportive oncology. Timely recognition of this febrile condition by differentiating it from other cancer-associated fevers, such as infection and drug reaction, is essential for effective patient management. Although the pathophysiology of neoplastic fever is not well understood, it is suspected to be cytokine mediated. In clinical practice, when a patient with cancer presents with unexplained fever, extensive diagnostic studies are needed to differentiate neoplastic fever from nonneoplastic fever. Only after excluding identifiable etiologies of fever can the diagnosis of neoplastic fever be suspected. According to our experience, the naproxen test is a safe and useful test in differentiating neoplastic fever from infectious fever in patients with cancer. In addition, naproxen and other nonsteroidal anti-inflammatory drugs have been effective in the management of neoplastic fever and offer a significant palliative benefit for the patient.

Anonymous (2002) Leukine (sargramostim). Package Insert Rev 0230-0233:1–2

Anonymous (2002) Neupogen (filgrastim). Physician Package Insert 1–29

Arnow PM, Flaherty JP (1997) Fever of unknown origin. Lancet 350:575–580PubMed

Ashford RF, McLachlan A, Nelson I, Mughal T, Pickering, D (1980) Pyrexia after cisplatin. Lancet 2:691–692PubMed

Beaupre DM, Talpaz M, Marini FC III, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R (1999) Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res 59:2971–2980PubMed

Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322PubMed

Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72:424–430PubMed

Bodel P (1974) Generalized perturbations in host physiology caused by localized tumors. Tumors and fever. Ann N Y Acad Sci 230:6–13PubMed

Bodel P, Ralph P, Wenc K, Long JC (1980) Endogenous pyrogen production by Hodgkin’s disease and human histiocytic lymphoma cell lines in vitro. J Clin Invest 65:514–518PubMed

10.

Bondy PK, Bodel P (1971) Mechanism of action of pyrogenic and antipyretic steroids in vitro. Ciba Found Symp 101–113

11.

Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520–535PubMed

12.

Browder AA, Huff JW, Petersdorf RG (1961) The significance of fever in neoplastic disease. Ann Intern Med 55:932–942PubMed

13.

Carter JJ, McLaughlin ML, Bern MM (1983) Bleomycin-induced fatal hyperpyrexia. Am J Med 74:523–525PubMed

14.

Cashman TM, Starns RJ, Johnson J, Oren J (1979) Comparative effects of naproxen and aspirin on fever in children. J Pediatr 95:626–629PubMed

15.

Chang JC (1987) How to differentiate neoplastic fever from infectious fever in patients with cancer: usefulness of the naproxen test. Heart Lung 16:122–127PubMed

16.

Chang JC (1988) Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage 3:141–144PubMed

17.

Chang JC (1989) Naproxen test in the differential diagnosis of fever of undetermined origin in patients with cancer. Cancer Ther Control 1:57–66

18.

Chang JC (1989) Neoplastic fever. A proposal for diagnosis. Arch Intern Med 149:1728–1730PubMed

19.

Chang JC, Appleby J, Bennett JM (1974) Nitroblue tetrazolium test in Hodgkin disease and other malignant lymphomas. Arch Intern Med 133:401–403PubMed

20.

Chang JC, Gross HM (1984) Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. Am J Med 76:597–603PubMed

21.

Chang JC, Gross HM (1985) Neoplastic fever responds to the treatment of an adequate dose of naproxen. J Clin Oncol 3:552–558PubMed

22.

Chung KF, Snashall PD (1983) Suppression of prolonged fever during treatment of pulmonary tuberculosis: importance of using twice versus single daily dose of prednisolone. Postgrad Med J 59:373–375PubMed

23.

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164–170PubMed

24.

Cunha BA (1996) Fever of unknown origin. Infect Dis Clin North Am 10:111–127PubMed

25.

Dinarello CA, Wolff SM (1978) Pathogenesis of fever in man. N Engl J Med 298:607–612PubMed

26.

Dinarello CA, Bunn PA (1997) Fever. Semin Oncol 24(3):288–298PubMed

27.

Economos K, Lucci JA III, Richardson B, Yazigi R, Miller DS (1995) The effect of naproxen on fever in patients with advanced gynecologic malignancies. Gynecol Oncol 56:250–254PubMed

28.

Fauci AS, Dale DC, Balow JE (1976) Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 84:304–315PubMed

29.

Feigin RD, Shackelford PG, Choi SC, Flake KK, Franklin FA Jr, Eisenberg CS (1971) Nitroblue tetrazolium dye test as an aid in the differential diagnosis of febrile disorders. J Pediatr 78:230–237PubMed

30.

Green HD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35PubMed

31.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMed

32.

Ishii E, Hara T, Mizuno Y, Ueda K (1988) Vincristine-induced fever in children with leukemia and lymphoma. Cancer 61:660–662PubMed

33.

Jacoby GA, Swartz MN (1973) Fever of undetermined origin. N Engl J Med 289:1407–1410PubMed

34.

Janssens AM, Offner FC, Van Hove WZ (2000) Bone marrow necrosis. Cancer 88:1769–1780PubMed

35.

Johnson M (1996) Neoplastic fever. Palliat Med 10:217–224PubMed

36.

Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029PubMed

37.

Kallio R, Bloigu A, Surcel HM, Syrjala H (2001) C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer 9:124–128PubMed

38.

Kathula SK, Shah K, Polenakovik H, Koduri J (2003) Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever. Support Care Cancer 11:258–259PubMed

39.

Keinanen-Kiukaanniemi S, Simila S, Kouvalainen K (1980) Oral antipyretic therapy evaluation of the propionic acid derivatives ibuprofen, ketoprofen, fenoprofen and naproxen. Padiatr Padol 15:139–144PubMed

40.

Klastersky J (1971) Effectiveness of adrenal corticosteroids in the management of severe bacterial infections. Rev Eur Etud Clin Biol 16:413–417PubMed

41.

Knupp C, Pekala PH, Cornelius P (1988) Extensive bone marrow necrosis in patients with cancer and tumor necrosis factor activity in plasma. Am J Hematol 29(4):215–221PubMed

42.

Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer 92:1684–1688PubMed

43.

Lobell M, Boggs DR, Wintrobe MM (1966) The clinical significance of fever in Hodgkin’s disease. Arch Intern Med 117:335–342

44.

Lusch CJ, Serpick AA, Slater L (1968) Antipyretic effect of indomethacin in patients with malignancy. Cancer 21:781–786PubMed

45.

Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP (2001) Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 18:99–107PubMed

46.

Park BH, Fikrig SM, Smithwick EM (1968) Infection and nitroblue-tetrazolium reduction by neutrophils. A diagnostic acid. Lancet 2:532–534PubMed

47.

Petersdorf RG (1965) Fever and cancer. Hosp Med 1:2–5

48.

Plaisance KI, Mackowiak PA (2000) Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. Arch Intern Med 160:449–456PubMed

49.

Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU (1986) Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 4:234–243PubMed

50.

Rawlins MD, Luff RH, Cranston WI (1970) Pyrexia in renal carcinoma. Lancet 1:1371–1373PubMed

51.

Schimpff SC (1986) Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 80:13–20

52.

Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse lareg cell lymphoma. J Clin Oncol 13:575–582PubMed

53.

Shah KA, Greenwald E, Levin J, Rosen N, Zumoff B (1982) Streptozocin-induced eosinophilia and fever: a case report. Cancer Treat Rep 66:1449–1451

54.

Smithson WA, Gronert GA, Moss KK (1983) Dantrolene and potentially fatal hyperthermia secondary to L-asparaginase. Cancer Treat Rep 67:318–319PubMed

55.

Sokal JE, Shimaoka K (1967) Pyrogen in the urine of febrile patients with Hodgkin’s disease. Nature 215:1183–1185

56.

Tsavaris N, Zinelis A, Karabelis A, Beldecos D, Bacojanis C, Milonacis N, Karvounis N, Kosmidis P (1990) A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med 228:451–455PubMed

57.

Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A(3):319–324PubMed

58.

Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnez A, Blockmans D, Bobbaers H (2003) From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 163:1033–1041PubMed

59.

Vanderschueren S, Knockaert DC, Peetermans WE, Bobbaers HJ (2003) Lack of value of the naproxen test in the differential diagnosis of prolonged febrile illnesses. Am J Med 115:572–575PubMed

60.

Vasser Stats (2004) Clinical calculator 1. From an observed sample: estimates of population prevalence, sensitivity, specificity, predictive values, and likelihood ratios. http://faculty.vassar.edu/lowry/clin1.html

61.

Wolfe LS, Pappius HM, Marion J (1976) The biosynthesis of prostaglandins by brain tissue in vitro. Adv Prostaglandin Thromboxane Res 1:345–355PubMed

Title: Neoplastic fever: a neglected paraneoplastic syndrome
Authors: Jason A. Zell
Jae C. Chang
Publication date: 01-11-2005
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 11/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-005-0825-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2005

Awareness of diagnosis, and information-seeking behavior of hospitalized cancer patients in Greece

Evaluation of a revised instrument to assess the needs of men diagnosed with prostate cancer

Information needs of patients with incurable cancer

The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care

Society News November 2005

Requests from professional care providers for consultation with palliative care consultation teams

Keynote webinar | Spotlight on antibody–drug conjugates in cancer